Evidence map›Paper›PMID 42902395›Full record

ArticleGenome biology2026

Profiling protein post-translational modifications in plasma-derived extracellular vesicles as fingerprints for breast cancer subtypes.

Marco Hadisurya, Hillary Andaluz Aguilar, I-Hsuan Chen, Mengting Xu, Juan Sebastian Paez, Rachit Bisht, Jyoti Singh, Zheng-Chi Lee, Amirhesam Mashaollahi, Anton Iliuk and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Marco Hadisurya *Department of Biochemistry, Purdue University, West Lafayette, IN, 47907, USA. marcohadisurya34@gmail.com.
Hillary Andaluz Aguilar *Department of Chemistry, Purdue University, West Lafayette, IN, 47907, USA.
I-Hsuan ChenDepartment of Biochemistry, Purdue University, West Lafayette, IN, 47907, USA.
Mengting XuSchool of Electrical and Computer Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Juan Sebastian PaezDepartment of Biochemistry, Purdue University, West Lafayette, IN, 47907, USA.
Rachit BishtSchool of Electrical and Computer Engineering, Purdue University, West Lafayette, IN, 47907, USA.
Jyoti SinghDepartment of Biochemistry, Purdue University, West Lafayette, IN, 47907, USA.
Zheng-Chi LeeDepartment of Biochemistry, Purdue University, West Lafayette, IN, 47907, USA.
Amirhesam MashaollahiDepartment of Biochemistry, Purdue University, West Lafayette, IN, 47907, USA.
Anton IliukTymora Analytical Operations, West Lafayette, IN, 47906, USA.
Weizhou ZhangDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, 32610, USA.
W Andy TaoDepartment of Biochemistry, Purdue University, West Lafayette, IN, 47907, USA. taow@purdue.edu.

Funding

University of Florida Health Cancer Center Support GrantP30CA247796 · NCI · UNIVERSITY OF FLORIDA · PI DIETMAR W SIEMANN · 2023 to 2026
$10.9M
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasisR01CA260239 · NCI · UNIVERSITY OF FLORIDA · PI ZHANG, WEIZHOU · 2021 to 2025
$2.5M
Dissecting signaling pathways and seeking EV phosphoproteins as novel biomarkers for Alzheimer's DiseaseR01AG064250 · NIA · PURDUE UNIVERSITY · PI TAO, W. ANDY · 2024 to 2024
$386k
Dr. and Mrs. James Robert Spenser Family P30CA247796National Science Foundation CHE-2404098NCI NIH HHS P30 CA247796NCI NIH HHS R01 CA260239NIA NIH HHS R01 AG064250NIH HHS 4R01AG064250NIH HHS R01CA260239
6 · The paper itself

Abstract

backgroundAddressing tumor heterogeneity in breast cancer research is crucial, given the distinct subtypes like triple-negative, luminal A/B, and HER2, requiring precise differentiation for effective treatment. This study introduces a non-invasive method by analyzing post-translationally modified proteins in plasma extracellular vesicles, which play a role in immune regulation and intercellular communication. Examining modifications like phosphorylation, acetylation and glycosylation in extracellular vesicles provides insights into breast cancer dynamics. One hundred and one plasma samples from luminal A/B breast cancer, triple-negative breast cancer and healthy individuals underwent discovery and validation experiments.

resultThe study identified over 28,000 unique non-modified peptides, 5,000 phosphopeptides, 680 acetyl peptides and 1,300 glycopeptides that are successfully characterized. Bioinformatics analyses revealed significant overexpression of 815 non-modified proteins, 3,958 phosphopeptides, 352 acetyl peptides and 895 glycopeptides in luminal A/B breast cancer or triple-negative breast cancer subtypes. Phosphorylated and glycosylated PD-L1 peptides emerge as potential markers for breast cancer, regardless of subtype. Aligning the findings with literature and PAM50 gene signatures highlights markers correlated with lower survival rates. The study also reports 123 scheduled parallel reaction monitoring analyses, leveraging machine learning to pinpoint a panel of specific modification sites with high accuracy for subtype differentiation.

conclusionsThis research reveals diagnostic markers and enhances understanding of the molecular landscape, contributing to more effective and personalized breast cancer diagnostics and treatments.

Indexed as

Breast NeoplasmsExtracellular VesiclesProtein Processing, Post-TranslationalAcetylationBiomarkers, TumorFemaleGlycosylationHumansPhosphorylationTriple Negative Breast NeoplasmsBiomarkers, TumorAcetylationBreast cancerExtracellular vesiclesGlycosylationLuminal ALuminal BPhosphorylationPlasmaPost-translational modificationsTriple-negative

Identifiers

PMID42902395
PMCPMC13685163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.